Herpes simplex encephalitis

Lore & Background

Herpes simplex encephalitis is a rare but severe infection of the brain caused primarily by HSV-1. Two-thirds of HSE cases occur in individuals already seropositive for HSV-1, few of whom have a history of recurrent orofacial herpes. About one third of cases result from an initial infection by HSV-1, predominantly in individuals under 18. The virus is thought to travel from a peripheral site on the face along a nerve axon to the brain, lying dormant in the trigeminal ganglion; the reason for reactivation remains unclear, though stress plays a role in animal models.

Reader's Guide

Herpes simplex encephalitis is significant as the most common cause of encephalitis in children and adults, though encephalitis in newborns and immunocompromised individuals is mainly caused by HSV-2. Without treatment, HSE results in rapid death in approximately 70% of cases, and survivors suffer severe neurological damage. Even with high-dose intravenous acyclovir, the disease is fatal in one-third of cases and causes serious long-term neurological damage in over half of survivors. Only 20% of treated patients recover with minor damage, and a small population of untreated survivors (2.5%) regain completely normal brain function. Earlier treatment within 48 hours of symptom onset improves the chances of a good recovery. HSE can also serve as a trigger of anti-NMDA receptor encephalitis, a secondary immunologic reaction associated with impaired neurocognitive recovery.

Did You Know?

• About 90% of herpes encephalitis cases are caused by HSV-1, the same virus that causes cold sores.
• Approximately half of individuals who develop HSE are over 50 years of age.
• Without treatment, HSE results in rapid death in approximately 70% of cases.
• About 30% of HSE patients develop anti-NMDA receptor encephalitis as a secondary immunologic reaction.

The Virus Behind the Storm

Herpes simplex encephalitis sits at the intersection of an extraordinarily common virus and a devastating neurological outcome. The culprit in roughly nine out of ten cases is HSV-1, the same agent responsible for cold sores, while HSV-2 accounts for the remaining tenth. A 2006 estimate placed HSV-1 infection at 57 percent of American adults, a figure that underscores how widespread the virus is even though most carriers never develop visible oral lesions. Transmission occurs through droplets, everyday casual contact, and occasionally sexual contact, making the reservoir of latent virus vast. Yet the leap from a peripheral infection to encephalitis is rare, with annual incidence estimated at two to four cases per million people, or roughly one in 500,000 per year. Demographically, the picture is mixed: about two-thirds of patients were already seropositive before the episode, while the remaining third contracted HSV-1 for the first time, a scenario seen predominantly in those under eighteen. Half of all HSE patients are over fifty, and in newborns and immunocompromised individuals, HSV-2 takes the lead as the encephalitic agent.

The Temporal Lobe Predilection and Clinical Picture

Once the virus reaches the brain, its signature is unmistakable: a relentless assault on the temporal lobes. Patients typically present with declining consciousness, confusion, and personality shifts, often with fever and seizures. Cerebrospinal fluid reveals elevated white blood cells without any bacterial or fungal pathogen. As the disease unfolds, electroencephalography first captures abnormalities in one temporal lobe before the electrical disturbance migrates to the contralateral lobe roughly seven to ten days later. Magnetic resonance imaging confirms the pattern, showing characteristic signal changes in the temporal regions, limbic system, inferior frontal lobes, and insular cortex, while the basal ganglia are typically spared. A striking early clue is the loss of smell, which may reflect the olfactory nerve's anatomical route into the temporal lobes. Language functions crumble—reading, writing, coherent speech, and comprehension of spoken words all deteriorate. The pathophysiology remains only partly understood: the virus is thought to reactivate from its dormant home in the trigeminal ganglion and travel along a nerve axon to the brain, though the precise trigger and route are still unclear, with stress implicated in animal models. Clinicians must also recognize that HSE can masquerade as a stroke.

The Diagnostic Gauntlet

Confirming herpes simplex encephalitis is a race against time. The current gold standard is polymerase chain reaction analysis of cerebrospinal fluid for HSV-1 or HSV-2 viral DNA, with 96 percent sensitivity and 99 percent specificity. Yet false negatives are a real hazard during the first seventy-two hours, when blood hemoglobin interferes, or after forty-eight hours of acyclovir therapy. For later confirmation, intrathecal HSV-specific IgM antibodies appear after ten to fourteen days, and antibodies against purified glycoprotein B offer 97 percent sensitivity and 100 percent specificity. Blood serology is essentially useless because HSV exposure is so widespread. Lumbar puncture often reveals elevated opening pressure, high protein, normal glucose, and a lymphocytic pleocytosis, occasionally tinged with red blood cells from temporal lobe hemorrhage. CT scans are performed first to exclude hemorrhage but have low early sensitivity, while MRI on T2 and FLAIR sequences provides far more definitive visualization of temporal, limbic, frontal, and insular involvement. Electroencephalography is abnormal in roughly two-thirds of patients, showing periodic lateralizing epileptiform discharges or sharp-and-slow complexes recurring every two to three seconds over the temporal regions. Because definitive testing takes days, clinicians are urged to begin acyclovir immediately upon suspicion.

Treatment, Mortality, and the Secondary Immune Storm

Even with modern antiviral therapy, herpes simplex encephalitis remains a medical emergency with sobering mortality statistics. The cornerstone of treatment is high-dose intravenous acyclovir, administered at ten milligrams per kilogram for adults and infused over one hour to protect the kidneys. In the rarer scenario of acyclovir-resistant HSV, foscarnet may be added as an off-label option. The stakes of delay are stark: without antiviral intervention, approximately seventy percent of patients die rapidly, and survivors are left with severe neurological damage. Even when acyclovir is given promptly, one-third of cases still prove fatal, and survivors frequently endure lasting cognitive and functional deficits. A particularly insidious complication is the secondary autoimmune reaction known as anti-NMDA receptor encephalitis, which develops in roughly thirty percent of HSE patients. This immune-mediated sequela is strongly associated with impaired neurocognitive recovery, meaning that even patients who survive the initial viral assault can face a second wave of neurological deterioration driven by their own immune system. The interplay between viral destruction and the resulting autoimmune response underscores why HSE demands management of a cascading neurological injury, not merely viral eradication.

Gallery